229 related articles for article (PubMed ID: 31490979)
21. Role of polymorphic bile salt export pump (BSEP, ABCB11) transporters in anti-tuberculosis drug-induced liver injury in a Chinese cohort.
Chen R; Wang J; Tang S; Zhang Y; Lv X; Wu S; Yang Z; Xia Y; Chen D; Zhan S
Sci Rep; 2016 Jun; 6():27750. PubMed ID: 27293027
[TBL] [Abstract][Full Text] [Related]
22. Association between
Wen J; Lv Z; Ding H; Fang X; Sun M
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29654162
[TBL] [Abstract][Full Text] [Related]
23. Collagen type XVIII alpha 1 chain (COL18A1) variants affect the risk of anti-tuberculosis drug-induced hepatotoxicity: A prospective study.
Cheng Y; Jiao L; Li W; Wang J; Lin Z; Lai H; Ying B
J Clin Lab Anal; 2021 Feb; 35(2):e23630. PubMed ID: 33296124
[TBL] [Abstract][Full Text] [Related]
24. Do genetic polymorphisms of B-cell CLL/lymphoma 2 confer susceptibility to anti-tuberculous therapy-associated drug-induced liver injury?
Lyu M; Jiao L; Zhou J; Li H; Meng Z; Xie W; Ren J; Bian Q; Ying B
Int J Infect Dis; 2020 Feb; 91():223-231. PubMed ID: 31838216
[TBL] [Abstract][Full Text] [Related]
25. The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.
Liu X; Ren S; Zhang J; Xu D; Jiang F; Jiang P; Feng J; Deng F
Ann Palliat Med; 2021 Jun; 10(6):6518-6534. PubMed ID: 34154362
[TBL] [Abstract][Full Text] [Related]
26. Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: a nested case-control study.
Chen S; Pan H; Chen Y; Lu L; He X; Chen H; Chen R; Zhan S; Tang S
Sci Rep; 2019 Oct; 9(1):14311. PubMed ID: 31586142
[TBL] [Abstract][Full Text] [Related]
27. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.
Mishra S; Daschakraborty S; Shukla P; Kapoor P; Aggarwal R
Natl Med J India; 2013; 26(5):260-5. PubMed ID: 25017831
[TBL] [Abstract][Full Text] [Related]
28. A Notch4 missense mutation is associated with susceptibility to tuberculosis in Chinese population.
Zhang J; Jiao L; Bai H; Wu Q; Wu T; Liu T; Hu X; Song J; Ying B
Infect Genet Evol; 2020 Mar; 78():104145. PubMed ID: 31838262
[TBL] [Abstract][Full Text] [Related]
29. CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
Deng R; Yang T; Wang Y; Tang N
Int J Tuberc Lung Dis; 2012 Dec; 16(12):1574-81. PubMed ID: 23131254
[TBL] [Abstract][Full Text] [Related]
30. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis.
Chang TE; Huang YS; Chang CH; Perng CL; Huang YH; Hou MC
J Chin Med Assoc; 2018 Feb; 81(2):111-118. PubMed ID: 29198550
[TBL] [Abstract][Full Text] [Related]
31. Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease.
Glas J; Seiderer J; Fischer D; Tengler B; Pfennig S; Wetzke M; Beigel F; Olszak T; Weidinger M; Göke B; Ochsenkühn T; Folwaczny M; Müller-Myhsok B; Diegelmann J; Czamara D; Brand S
Inflamm Bowel Dis; 2011 Sep; 17(9):1917-24. PubMed ID: 21830270
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population.
Zhang J; Ma S; Zhou W; Feng J; Kang Y; Yang W; Zhang H; Deng F
Toxicol Appl Pharmacol; 2023 Dec; 481():116770. PubMed ID: 37995809
[TBL] [Abstract][Full Text] [Related]
33. Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study.
Ji GY; Wang Y; Wu SQ; Liu QQ; Wu JC; Zhang MM; Sandford AJ; He JQ
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706680
[TBL] [Abstract][Full Text] [Related]
34. Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study.
Sun Q; Liu HP; Zheng RJ; Wang P; Liu ZB; Sha W; Xiao HP
Clin Drug Investig; 2017 Dec; 37(12):1125-1136. PubMed ID: 28900877
[TBL] [Abstract][Full Text] [Related]
35. Global DNA hypomethylation of Alu and LINE-1 transposable elements as an epigenetic biomarker of anti-tuberculosis drug-induced liver injury.
Udomsinprasert W; Sakuntasri W; Jittikoon J; Chaikledkaew U; Honsawek S; Chantratita W; Wattanapokayakit S; Mahasirimongkol S
Emerg Microbes Infect; 2021 Dec; 10(1):1862-1872. PubMed ID: 34467830
[TBL] [Abstract][Full Text] [Related]
36. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
Suvichapanich S; Fukunaga K; Zahroh H; Mushiroda T; Mahasirimongkol S; Toyo-Oka L; Chaikledkaew U; Jittikoon J; Yuliwulandari R; Yanai H; Wattanapokayakit S; Tokunaga K
Pharmacogenet Genomics; 2018 Jul; 28(7):167-176. PubMed ID: 29781872
[TBL] [Abstract][Full Text] [Related]
37. Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity.
Wang N; Guo S; Liu H; Ding Y; Yao R; Liu Z; Zhu H; Chen X; Yang X; Chen X; Lu Y
Xenobiotica; 2022 May; 52(5):520-526. PubMed ID: 35723590
[TBL] [Abstract][Full Text] [Related]
38. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study.
Chen R; Zhang Y; Tang S; Lv X; Wu S; Sun F; Xia Y; Zhan SY
J Clin Pharm Ther; 2015 Feb; 40(1):110-5. PubMed ID: 25250564
[TBL] [Abstract][Full Text] [Related]
39. Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study.
Yang M; Zhang H; Tao B; Pan H; Lu L; Yi H; Tang S
J Clin Pharm Ther; 2019 Aug; 44(4):534-542. PubMed ID: 30776144
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of inflammatory bowel disease.
Andersen V; Christensen J; Ernst A; Jacobsen BA; Tjønneland A; Krarup HB; Vogel U
World J Gastroenterol; 2011 Jan; 17(2):197-206. PubMed ID: 21245992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
